About 20 kilometers north of San José, a university laboratory keeps hundreds of venomous snakes on purpose. The snakes are not the product. Their venom is the raw material for antivenom, and, as a side effect, for one of the clearest lessons in how a molecule becomes a medicine. Most molecules never make it. The ones that do get redesigned, tested and documented until the animal they came from is almost beside the point.
The lab that keeps vipers on purpose
The Instituto Clodomiro Picado was established in 1970 as a research unit of the Universidad de Costa Rica. It carries the name of Clodomiro Picado Twight, the scientist who in the 1920s set out to study snakebite as a public health problem. Costa Rica made its first lot of antivenom in 1967, through a joint effort of the university, the Ministry of Health and a US military mission, and the institute followed three years later.
The reason is local. Most snakebites in Costa Rica come from one pit viper, Bothrops asper, and the burden falls on rural communities, where reaching antivenom takes time. The institute’s antivenoms now reach Central America, Ecuador, Nigeria, Sri Lanka and Papua New Guinea. When AFP visited in 2010, the institute was working from about 800 snakes and producing roughly 100,000 doses of antivenom a year. Horses receive small, non-lethal injections of venom over three months, and antibodies are then taken from their plasma. Those figures are sixteen years old, so current output may differ.
The stakes are global. The World Health Organization estimates that between 81,000 and 138,000 people die from snakebite every year.
Venom is a mixture, and mixtures have to be taken apart
Venom is not one substance. It is a crowded mixture of enzymes, small proteins and peptides, each with its own target in the body. To build a better antivenom, someone has to separate that mixture and find out which parts do the damage.
In 2018, the Costa Rican institute joined the Technical University of Denmark and the British company IONTAS on a paper in Nature Communications about black mamba venom. The team split the venom into fractions by reversed-phase HPLC and located the dendrotoxins, small neurotoxins that contribute heavily to its toxicity. Human antibodies against those toxins were then selected in the laboratory, and cocktails of them protected mice from dendrotoxin-mediated neurotoxicity. The authors described it as a proof of concept, a long way from a treatment for people.
The institute does not make venom-derived drugs. It does the work that has to come first: telling one venom from another, fraction by fraction, and knowing exactly what each piece is. The chromatography column in that workflow belongs to the same family of instrument that prints a purity figure on a certificate of analysis for a synthetic peptide. In a venom lab it answers “what is in here?” On a certificate it answers “how much of this vial is the thing on the label?”
The first venom drug threw most of the venom away
Captopril, approved in 1981, was the first drug built from an animal toxin. Its starting point was a bradykinin-potentiating factor in the venom of Bothrops jararaca, a South American relative of Costa Rica’s own pit viper. The natural peptide was expensive to synthesize and could not be taken by mouth, so chemists redesigned it into a much smaller molecule. The medicine that reached patients was not the venom peptide. It was an engineered descendant, and it went on to become a widely used blood pressure drug.
Others followed. Ziconotide, approved in 2004, is a synthetic version of a 25-amino-acid peptide from the venom of the cone snail Conus magus, given into the spinal canal for severe chronic pain. Exenatide, approved in 2005, is a synthetic version of exendin-4 from Gila monster saliva and is used in type 2 diabetes. A 2024 review counted eleven approved venom-derived drugs in total. For a field that has been studied for more than forty years, that is a short list.
The short list has a reason. Engineering a venom peptide into a drug is a series of trades. The same 2024 review notes that adding charged amino acids to the ends of a peptide can improve delivery and extend its half-life, but generally lowers its potency. Every fix costs something, and each cost has to be measured.
What those approvals had to prove
A drug has to show a defined structure, controlled manufacturing, and human trials built to answer a specific question. Regulators review the whole file. Coming from a viper, a snail or a lizard bought none of those eleven a shortcut. A peptide found in venom has no more standing than one invented at a bench, and what counts is the record behind it.
Where a catalog vial sits in that picture
A research peptide on a supplier’s shelf has none of that record. It is not an approved medicine, and in Costa Rica medicines answer to the Ministerio de Salud. Online, the line between the two categories blurs easily, so it helps to see how a supplier draws it. A local supplier such as Peptides Costa Rica says as much in its FAQ at peptidescostarica.net/faq-costa-rica: its products are research peptides supplied for laboratory and research purposes, they are not registered with the Ministerio de Salud as pharmaceutical products, and the company gives no dosing guidance, protocols or medical advice.
That statement settles what the products are not. It says nothing about what is in the vial, and the honest answer to that question has to come from paperwork. The venom laboratory’s habits show what the paperwork should contain.
What the paperwork should show
Identity and purity are two different questions. Mass spectrometry confirms that the molecule is the right one, by matching its measured mass to the expected molecular weight. HPLC reports what share of the sample is that molecule. A certificate that gives a purity percentage with no identity result has answered half of the question, and a high percentage attached to the wrong compound is still the wrong compound.
Three further checks cost nothing. The batch number on the certificate should match the one on the vial. The certificate should include the actual chromatogram, because a bare figure can’t be audited. The test date should be recent enough to describe the material that is on the shelf.
Peptides Costa Rica says that every batch has a certificate of analysis and a specification sheet published before it goes on sale, and that each product page lists compound name, vial size, physical form, molecular weight, purity as tested and storage requirements. Those are claims a buyer can test in ten minutes. Open its published catalog, choose any product page, find the batch certificate, and see whether both the identity result and the chromatogram are there. A supplier that publishes what it claims makes that check easy, and one that does not makes it impossible.
The record is the product
The antivenom made in Vázquez de Coronado is trusted because each venom has been fractionated, each toxin named, each antibody tested against a specific target. Eleven venom-derived drugs reached patients because their makers could show what was in the vial and what it did. A supplier of research material can meet only the first half of that standard, and it should meet that half completely.